Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) Insider Sells 10,300 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 10,300 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $1.01, for a total value of $10,403.00. Following the sale, the insider now owns 316,604 shares in the company, valued at approximately $319,770.04. The trade was a 3.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, December 19th, Jonathan Zalevsky sold 51,115 shares of Nektar Therapeutics stock. The stock was sold at an average price of $0.94, for a total transaction of $48,048.10.

Nektar Therapeutics Stock Performance

NKTR opened at $0.93 on Monday. The company has a fifty day moving average of $0.92 and a two-hundred day moving average of $1.12. Nektar Therapeutics has a fifty-two week low of $0.63 and a fifty-two week high of $1.93. The stock has a market capitalization of $171.95 million, a price-to-earnings ratio of -1.11 and a beta of 0.58.

Hedge Funds Weigh In On Nektar Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Securities LLC grew its holdings in Nektar Therapeutics by 56.3% in the fourth quarter. Two Sigma Securities LLC now owns 27,654 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 9,958 shares during the period. Harvest Investment Services LLC acquired a new stake in Nektar Therapeutics in the 4th quarter valued at $27,000. US Asset Management LLC purchased a new stake in Nektar Therapeutics in the 4th quarter worth $31,000. Valence8 US LP acquired a new position in Nektar Therapeutics during the third quarter worth $34,000. Finally, Intech Investment Management LLC purchased a new position in Nektar Therapeutics during the third quarter valued at $41,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on NKTR shares. HC Wainwright reiterated a “buy” rating and issued a $6.50 price objective on shares of Nektar Therapeutics in a research note on Monday, January 13th. Piper Sandler began coverage on Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 price target on the stock. Finally, B. Riley initiated coverage on Nektar Therapeutics in a research note on Wednesday, January 8th. They set a “buy” rating and a $4.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $4.08.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.